Quarterly ResultMay 14, 2026, 04:14 PM
Elutia Q1 Net Sales $3.1M; Highlights NXT-41x Progress
AI Summary
Elutia Inc. reported Q1 2026 net sales of $3.1 million, a 6% increase year-over-year, alongside a net loss of $7.5 million. The company highlighted significant progress on its NXT-41x drug-eluting biomatrix, including advancing FDA review for NXT-41, bringing a new automated manufacturing process online to support over 80% gross margin, and confirming a substantial market opportunity in breast reconstructive surgery. Elutia also noted $36.5 million in cash and escrowed proceeds and is exploring strategic options for its SimpliDerm and Cardiovascular product lines.
Key Highlights
- Q1 2026 net sales increased 6% to $3.1 million.
- Q1 2026 net loss was $7.5 million, compared to $3.9 million in Q1 2025.
- Adjusted gross margin improved to 66.5% in Q1 2026 from 55.9% in Q1 2025.
- Total cash and escrow funds stood at $36.5 million as of March 31, 2026.
- NXT-41 FDA 510(k) clearance is anticipated in Q4 2026, with NXT-41x clearance in H1 2027.
- New automated manufacturing process targets gross margin above 80% at scale.
- Company is exploring divestiture of SimpliDerm and evaluating inquiries for its Cardiovascular product line.